ReviewCurrent cancer drug targets2026
Molecular Mechanism and Research Progress of Sphingolipid Metabolism in Regulating Radiation-induced Apoptosis Using Pan-cancer Analysis.
Review in Current cancer drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plasma Sphingolipid Profiling Predicts Radiosensitivity in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Radiotherapy stands as a cornerstone in cancer therapy, with nuclear DNA acknowledged as the principal target molecule for radiation-induced cellular demise or injury. Nonetheless, an expanding body of contemporary research elucidates the significant contribution of sphingolipids to radiation-induced cell death, particularly in modulating radiationinduced apoptosis. Radiation can instigate apoptosis through multiple pathways of sphingolipid metabolism, encompassing the activation of ceramide synthase, acid sphingomyelinase, neutral sphingomyelinase, sphingosine-1-phosphate lyase, and sphingosine-1-phosphate phosphatase, and the inhibition of sphingosine kinase-1. The disruption of sphingolipid metabolism leads to an increase in pro-apoptotic sphingolipid ceramide and sphingosine and a decrease in anti-apoptotic sphingolipid sphingosine-1-phosphate, which ultimately triggers apoptosis in tumor cells. The diminished or absent response of sphingolipids to radiation represents one of the contributors to radioresistance. In this context, numerous interventions targeting sphingolipids have been utilized to augment radiosensitivity in tumor tissue and mitigate radiation-induced damage in normal tissue, demonstrating efficacy both
Indexed as
Identifiers
39844563What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.